Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14262395 | 0.84 | CYP19A1 (0.37) | ACHECCNE1CDK2CYP19A1ALDH1A1 | |
| SCHEMBL27048554 | 0.84 | CCNE1 (0.35) | ACHECCNE1CDK2CYP19A1LRRK2 | |
| SCHEMBL17324236 | 0.83 | CYP19A1 (0.38) | ACHECYP19A1POLB | |
| SCHEMBL21152290 | 0.81 | CYP19A1 (0.39) | ACHECYP19A1POLB | |
| SCHEMBL19296375 | 0.81 | CYP1A2 (0.41) | CYP1A2CCNE1CDK2ALDH1A1GLA | |
| SCHEMBL23308741 | 0.80 | CCNE1 (0.38) | CCNE1CDK2CYP19A1ALDH1A1GLA | |
| SCHEMBL25514792 | 0.79 | CCNE1 (0.41) | CCNE1CDK2CYP19A1ALDH1A1HTT | |
| SCHEMBL13542691 | 0.78 | CYP1A2 (0.40) | CYP1A2ALDH1A1POLB | |
| SCHEMBL20362413 | 0.78 | CYP1A2 (0.40) | CYP1A2CYP19A1 | |
| SCHEMBL19296374 | 0.77 | CYP1A2 (0.39) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-9730976-B2 | Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers | BIONTECH AG (DE) | 2017-08-15 | — | — | US | disclosed |
| US-20160317605-A1 | New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers | BIONTECH AG (DE) | 2016-11-03 | — | — | US | disclosed |
| US-9321808-B2 | Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers | BIONTECH AG (DE) | 2016-04-26 | — | — | US | disclosed |
| US-20150119342-A1 | New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317605-A1 | New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers | BID, BIRC2, API5 | CYP1A2 4527/4885ACHE 4449/4885CCNE1 686/4885 |
| US-20150119342-A1 | New Homo- and Heterodimeric SMAC Mimetic Compounds as Apoptosis Inducers | BID, BIRC2, API5 | CYP1A2 4527/4885ACHE 4449/4885CCNE1 686/4885 |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | CYP1A2 4519/4885ACHE 4625/4885CCNE1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.